02-OCT-2026 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     4132 374 170 89 35 12 02/06/2019 484 187
Screened at PD     1574 248 114 59 19 8      
Pre-Screened prior to PD     2531 110 50 27 15 4      
Treatment-naive     27 16 6 3 1 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     542 29 12 7 2 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2281 303 140 69 22 10      
Screened at PD     1341 244 116 59 19 8      
Pre-Screened prior to PD     854 38 16 6 1 0      
Treatment-naive     27 17 6 3 1 1      
After PD on a Lung_MAP Sub-Study     59 4 2 1 1 1      
 
Sub-Study Assignments (open studies only)
S1800E     463 262 123 59 20 8      
S1900G     41 9 6 3 0 0      
S1900J     18 5 0 0 0 0      
S1900K     45 23 7 3 1 1      
S1900N     4 4 4 4 1 1      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     679 142 67 34 12 4      
Initial sub-study registrations     666 141 66 34 12 4      
Subsequent sub-study registrations     13 1 1 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 142 117 57 31 11 4 05/22/2025 361 119
Docetaxel plus Ramucirumab Y   72 59 29 14 5 3      
Cemiplimab plus Docetaxel and Ramucirumab Y   70 58 28 17 6 1      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   44 28 6 3 1 0 0 05/05/2023 339 107
Capmatinib + Osimertinib + Ramucirumab Y   16 4 2 1 0 0      
Capmatinib + Osimertinib Y   12 2 1 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 4 2 0 0 0 0 11/19/2024 282 86
Amivantamab Hyaluronidase Y   4 2 0 0 0 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 30 16 6 1 0 0 08/08/2024 297 92
Tepotinib + Ramucirumab Y   21 12 5 1 0 0      
Tepotinib Y   9 4 1 0 0 0      
S1900N: AGAs: SG alone, I alone, or SG + I   117 1 1 1 1 1 0 09/22/2026 132 40
Sacituzumab Govitecan Y   1 1 1 1 1 0